Venkateswaran Vellaichamy Swaminathan

Venkateswaran Vellaichamy Swaminathan

Auto-generated profile, based on publicly available information

Venkateswaran Vellaichamy Swaminathan

Department of Paediatric Hematology, Oncology and Blood and Marrow Transplantation Apollo Cancer Institutes Chennai India

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2020 in Pediatric Transplantation
Verified
Journal Article
Closed access
PDF file
VSVenkateswaran Vellaichamy Swaminathan
Venkateswaran Vellaichamy Swaminathan
NRNikila Ravichandran
Nikila Ravichandran
KRKesavan Melarcode Ramanan
Kesavan Melarcode Ramanan
SMSatish Kumar Meena
Satish Kumar Meena
HVHarika Varla
Harika Varla
RRRevathi Raj
Revathi Raj

29 December 2018 in Indian Pediatrics
Verified
Journal Article
Closed access
PDF file
SPShivani Patel
Shivani Patel
VSVenkateswaran Vellaichamy Swaminathan
Venkateswaran Vellaichamy Swaminathan
VMV Sr. Mythili
V Sr. Mythili
MVM Sr. Venkatadesikalu
M Sr. Venkatadesikalu
MSMeena Sivasankaran
Meena Sivasankaran
RRRevathi Raj
Revathi Raj

31 May 2019 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
VSVenkateswaran Vellaichamy Swaminathan
Venkateswaran Vellaichamy Swaminathan
RURamya Uppuluri
Ramya Uppuluri
SPShivani Patel
Shivani Patel
MSMeena Sivashankaran
Meena Sivashankaran
NRNikila Ravichandran
Nikila Ravichandran
RRRevathi Raj
Revathi Raj

28 January 2019 in Indian Journal of Hematology and Blood Transfusion
Verified
Journal Article
Open access
PDF file
RURamya Uppuluri
Ramya Uppuluri
MSMeena Sivasankaran
Meena Sivasankaran
SPShivani Patel
Shivani Patel
VSVenkateswaran Vellaichamy Swaminathan
Venkateswaran Vellaichamy Swaminathan
NRNikila Ravichandran
Nikila Ravichandran
RRRevathi Raj
Revathi Raj
We present our experience in haploidentical stem cell transplantation (haplo SCT) in children with benign disorders. We performed a retrospective study where children aged up to 18 years diagnosed to have benign disorders and underwent haplo SCT from 2002 to September 2017 were included. Of the 54 children, the most common indications were Fanconi anaemia 12 (22%), severe aplastic anaemia 8 (14%) and primary immune deficiency disorders (PID) 25 (46%). Post-transplant cyclophosphamide (PTCy) was used in 41 (75.9%) and ex vivo T depletion in 13 (24.1%). Engraftment rates were 70% with acute graft versus host disease in 36% and cytomegalovirus reactivation in 55% children. There was a statistically significant difference found between survival with siblings as donors as compared to parents (p value 0.018). Overall survival was 60% which is the 1-year survival, with 68% survival among those with PIDs. Cytokine release syndrome was noted in 12/41 (29%) of children who received T replete graft and PTCy. In children over 6 months of age, PTCy at a cost of INR 1200 provides cost effective T cell depletion comparable with TCR α/β depletion priced at INR 1200,000. Haplo SCT is feasible option for cure in children with benign disorder.